Phase III data show investigational compound empagliflozin reduced blood glucose in adults with Type 2 Diabetes treated with basal insulin

Phase III data show investigational compound empagliflozin reduced blood glucose in adults with Type 2 Diabetes treated with basal insulin
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news